JP2010530371A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010530371A5 JP2010530371A5 JP2010512322A JP2010512322A JP2010530371A5 JP 2010530371 A5 JP2010530371 A5 JP 2010530371A5 JP 2010512322 A JP2010512322 A JP 2010512322A JP 2010512322 A JP2010512322 A JP 2010512322A JP 2010530371 A5 JP2010530371 A5 JP 2010530371A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- hydroxy
- pregnan
- derivative
- analog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 70
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- AURFZBICLPNKBZ-SYBPFIFISA-N brexanolone Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1 AURFZBICLPNKBZ-SYBPFIFISA-N 0.000 claims description 16
- AURFZBICLPNKBZ-UHFFFAOYSA-N Pregnanolone Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(=O)C)C1(C)CC2 AURFZBICLPNKBZ-UHFFFAOYSA-N 0.000 claims description 15
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 9
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 9
- 206010027175 memory impairment Diseases 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 230000003111 delayed effect Effects 0.000 claims description 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 5
- 238000013268 sustained release Methods 0.000 claims description 5
- 239000012730 sustained-release form Substances 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 claims description 5
- 210000004556 brain Anatomy 0.000 claims description 4
- 210000005036 nerve Anatomy 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 238000002513 implantation Methods 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 208000020358 Learning disease Diseases 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 150000003146 progesterones Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94318707P | 2007-06-11 | 2007-06-11 | |
| PCT/US2008/066558 WO2008154579A1 (en) | 2007-06-11 | 2008-06-11 | Allopregnanolone in a method for enhancing neurological function (alzheimer disease) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010530371A JP2010530371A (ja) | 2010-09-09 |
| JP2010530371A5 true JP2010530371A5 (enExample) | 2012-06-07 |
Family
ID=39672702
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010512322A Pending JP2010530371A (ja) | 2007-06-11 | 2008-06-11 | 神経学的機能を増強するための作用物質、組成物および方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US8969329B2 (enExample) |
| EP (1) | EP2167098B1 (enExample) |
| JP (1) | JP2010530371A (enExample) |
| WO (1) | WO2008154579A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2457923B1 (en) * | 2009-07-24 | 2016-01-27 | Kyowa Hakko Kirin Co., Ltd. | Sterol derivative |
| RS59734B1 (sr) | 2012-01-23 | 2020-02-28 | Sage Therapeutics Inc | Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina |
| EP2887944B1 (en) | 2012-08-21 | 2021-10-06 | Sage Therapeutics, Inc. | Allopregnanolone for treating refractory status epilepticus |
| US9757391B2 (en) | 2012-11-09 | 2017-09-12 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| EP2925327B1 (en) | 2012-11-30 | 2024-01-10 | The Regents of The University of California | Allopregnanolone for treating, reducing or mitigating symptoms of post-partum depression |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| AU2017229656B2 (en) | 2016-03-08 | 2022-09-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JP7378781B2 (ja) * | 2016-09-07 | 2023-11-14 | グリア エルエルシー | 脳神経の薬理学的な経皮活性化による神経変性障害に関連する症状の治療 |
| EP4017498A4 (en) * | 2019-08-19 | 2022-11-09 | Arizona Board of Regents on behalf of the University of Arizona | TOPICAL NEUROSTEROID FORMULATIONS |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4897388A (en) * | 1988-12-20 | 1990-01-30 | Geriatric Research Institute, Inc. | Method of treating Alzheimer's disease |
| IL110309A0 (en) * | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| US5939545A (en) * | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| PL185523B1 (pl) * | 1995-06-06 | 2003-05-30 | Cocensys Inc | Neuroaktywne steroidy z grupy pochodnych androstanu i pregnanu oraz kompozycja farmaceutyczna |
| WO1999045931A1 (en) | 1998-03-11 | 1999-09-16 | Baeckstroem Torbjoern | Epiallopregnanolone in the treatment of cns disorders |
| US6552010B1 (en) * | 1999-11-12 | 2003-04-22 | Genelabs Technologies, Inc. | Treatment of SLE with dehydroepiandrosterone |
| US20020072509A1 (en) * | 2000-10-11 | 2002-06-13 | Stein Donald Gerald | Methods for the treatment of a traumatic central nervous system injury |
| PL378812A1 (pl) * | 2003-02-13 | 2006-05-29 | Pfizer Products Inc. | Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I |
| WO2005009359A2 (en) * | 2003-07-15 | 2005-02-03 | Roberta Diaz Brinton | Agents, compositions and methods for enhancing neurological function |
| US20050020552A1 (en) * | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
| US8604011B2 (en) | 2004-09-27 | 2013-12-10 | The Regents Of The University Of California | Therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| WO2007025064A2 (en) | 2005-08-24 | 2007-03-01 | The Miriam Hospital | METHODS OF USING SELECTIVE llβ-HSD INHIBITORS TO TREAT GLUOCORTICOID ASSOCIATED STATES |
-
2008
- 2008-06-11 JP JP2010512322A patent/JP2010530371A/ja active Pending
- 2008-06-11 US US12/526,604 patent/US8969329B2/en active Active
- 2008-06-11 WO PCT/US2008/066558 patent/WO2008154579A1/en not_active Ceased
- 2008-06-11 EP EP08795899.7A patent/EP2167098B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010530371A5 (enExample) | ||
| JP2018520189A5 (enExample) | ||
| JP2011511789A5 (enExample) | ||
| BR112014004845A2 (pt) | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| CA2588296A1 (en) | Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease | |
| BR112014004741A2 (pt) | pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada | |
| RU2013154699A (ru) | Сцилло-инозитол для применения в лечении поведенческих и психических расстройств | |
| JP2012502047A5 (enExample) | ||
| AR056824A1 (es) | Tableta de neramexano con matriz de liberacion modificada | |
| AU2022202218A1 (en) | Combination Therapy Using Acamprosate And D-Cycloserine | |
| JP2016505050A5 (enExample) | ||
| WO2007044062A8 (en) | Bile preparations for gastrointestinal disorders | |
| EP2498786A1 (fr) | Médicament inhalable à base de xénon pour traiter ou pour prévenir les dyskinésies induites | |
| RU2008134143A (ru) | Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения | |
| JP2020531543A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| JP2003535134A (ja) | 痴呆治療剤 | |
| JP2022536331A (ja) | シヌクレイノパチーの治療 | |
| Deschaux et al. | Influence of a GABAB and GABAC receptor antagonist on sleep–waking cycle in the rat | |
| Hubble | Novel drugs for Parkinson's disease | |
| US20230110065A1 (en) | Combination of anethole trithione or its derivative, 4-oh-anethole trithione, with doxycycline or minocycline for the use thereof in the treatment of parkinson's disease | |
| JP2017511386A5 (enExample) | ||
| US20140356343A1 (en) | Composition for treating parkinson's disease | |
| ES2969657T3 (es) | Tratamiento de trastorno de síndrome postraumático | |
| US10966988B2 (en) | Method for smoking cessation |